The Food and Drug Administration issued a Complete Response Letter to Opko Health Inc. (NYSE: OPK) for its New Drug Application for RAYALDEE to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The stock price tumbled $1.17 to close at $9.90.
Opko Health receives complete response letter
March 30, 2016 at 16:33 PM EDT
